Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neovasc Inc. NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Post by onions7777on Apr 17, 2018 7:47am
224 Views
Post# 27895758

Rimbus

RimbusDon't get me wrong, you're obviously a smart person, but you are not looking at this stock the right way.

First, these public reports everyone likes to quote are just the tip of the iceburg, and using other companies who failed in the past as a model is pointless. There is much more happening behind the scences that nobody is aware of. Frosts advisors, who are much smarter than us, wouldn't say "the stock isn't going anywhere but hey stop selling and buy a million shares @.062"

The company could have sold, closed the doors, and BODs could have walked away with some good coin. They didn't. I don't think anyone would stick around if there was a possibility for failure.

Looking forward, I agree analysts targets of $1.00+ is absurd, but this has every indication of reaching .50 by year end. Take all the PR, positive and negative, throw it out the door and cruch the finacials. This company is starting fresh. Valuate it properly and you will see for yourself.

With volume at @ 100M+ everyday, its pretty obvious its just getting flipped. When the cash injection was annouced last week, the price spiked then dropped. Again people making a quick buck. But what caught my eye was the size of the buys. Big players starting to jump in.

Now, I would agree 100% with you and start running for the hills if I notice resignations of directors, BSX selling their shares, and margins starting to decrease. Neovascs most important finacial metrics are all pointing up and have increased significatly TTM.  

Seeing past the noise of speculation, and using logic to look forward does wonders for investing :) 

<< Previous
Bullboard Posts
Next >>